Bearish flow noted in Crispr Therapeutics with 1,217 puts trading, or 2x expected. Most active are Jan-24 35 puts and Oct-23 65 calls, with total volume in those strikes near 1,400 contracts. The Put/Call Ratio is 1.86, while ATM IV is up nearly 9 points on the day. Earnings are expected on October 31st.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRSP:
- Crispr Therapeutics put volume heavy and directionally bearish
- Editas Medicine upgraded to Buy from Hold at Stifel
- CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
- Crispr Therapeutics initiated with a Buy at Mizuho
- Crispr Therapeutics Chairman Rodger Novak stepping down, CEO Kulkarni succeeds